Blopin

Candesartan cilexetil

HTN. Heart failure & impaired left ventricular systolic function (left ventricular ejection fraction ≤40%).

HTN Initially 4 mg daily, may be increased to 16 mg daily. Heart failure Usual recommended initial dose: 4 mg once daily, may be increased to 32 mg or to the highest tolerated dose by doubling the dose w/ at least 2-wk interval.

May be taken with or without food.

Hypersensitivity. Concomitant use w/ aliskiren in patients w/ DM or moderate to severe renal impairment (GFR <60 mL/min/1.73 m²). Severe hepatic impairment &/or cholestasis. 2nd & 3rd trimester of pregnancy & lactation.

Monitor BP, serum creatinine K levels periodically. Patients whose vascular tone & renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system, severe CHF; renal impairment; haemodialysis; unilateral or bilateral renal artery stenosis; patients w/ vol- & salt-depletion secondary to salt restriction, prolonged diuretic therapy, heart failure or dialysis; surgery/anaesth; aortic & mitral valve stenosis (obstructive hypertrophic cardiomyopathy); primary hyperaldosteronism; CHF; history of angioedema associated w/ or unrelated to ACE or angiotensin II receptor therapy. Avoid concomitant use w/ ACE inhibitor in heart failure patients & K-sparing diuretics. May affect ability to drive or operate machinery. Childn & adolescents <18 yr. Elderly >75 yr.

Dizziness/vertigo, headache; resp infections; hyperkalemia. leukopenia, neutropenia & agranulocytosis; nausea; increased liver enzymes; angioedema; back pain; arthralgia; myalgia; kidney disorders including kidney failure in certain patients.

Angiotensin II Antagonists

C09CA06 - candesartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.

G